AbbVie said the results of an analysis of three Phase III trials evaluating Imbruvica (ibrutinib) in treating chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) were presented at the 17th International Workshop on Chronic Lymphocytic Leukemia (iwCLL) biennial meeting in New York.
AbbVie said 23 abstracts, including data on approved and investigational oncology medicines, have been accepted for presentations at the 53rd annual meeting of the American Society of Clinical Oncology (ASCO) on June 2-6 in Chicago.
A gruesome potential side effect of stem cell or bone marrow transplants in oncology patients may soon meet its match in AbbVie’s Imbruvica, which has been accepted for review by the FDA for chronic graft-versus-host disease.
Global biopharmaceutical company AbbVie has received priority review from the Japanese Ministry of Health, Labour and Welfare for Glecaprevir/Pibrentasvir, its drug for the treatment of chronic hepatitis C.
The U.S. Food and Drug Administration approved AbbVie’s IMBRUVICA for treatment of relapsed/refractory marginal zone lymphoma in patients who require systemic therapy and have received at least one prior anti-CD 20-based therapy.
The AbbVie investigational, pan-genotypic, ribavirin-free regimen of glecaprevir (ABT-493)/Pibrentasvir (ABT-530) (G/P) achieved high SVR12 rates after eight weeks of treatment in Japanese patients with genotype 1 (GT1) chronic hepatitis C virus (HCV) infections without cirrhosis.
For stepping up during a 2015 natural disaster to partner with the International Medical Corps in Nepal, Abbvie recently received a Global Citizen Award, honoring its humanitarian actions in the wake of a destructive earthquake.
Leaders at AbbVie, a worldwide biopharmaceutical company, recently announced that it has launched its phase-three clinical trial concerning venetoclax, which is designed to treat patients who have relapsed or refractory multiple myeloma.
AbbVie, a worldwide biopharmaceutical company, recently announced that it has gained approval from the U.S. Food and Drug Administration (FDA) to use its once-daily Viekira XR formula to treat genotype 1 chronic hepatitis C.
Boehringer Ingelheim recently announced that its phase-two study results show that the company’s new treatment, IL-23 inhibitor risankizumab, induces remission in patients who have moderate-to-severe Crohn’s disease.